Novo Nordisk, Eli Lilly fall after Trump comments on weight loss drug pricing
Investing.com - J&J (NYSE: JNJ) reported third quarter EPS of $2.80, $0.04 better than the analyst estimate of $2.76. Revenue for the quarter came in at $23.99B versus the consensus estimate of $23.76B.
Guidance
J&J sees FY 2025 EPS of $10.80-$10.90 versus the analyst consensus of $10.85.
J&J sees FY 2025 revenue of $93.50B-$93.90B versus the analyst consensus of $93.46B.
J&J’s stock price closed at $190.90. It is up 17.13% in the last 3 months and up 16.33% in the last 12 months.
J&J saw 14 positive EPS revisions and 3 negative EPS revisions in the last 90 days. See J&J’s stock price’s past reactions to earnings here.
According to InvestingPro, J&J’s Financial Health score is "good performance".
Check out J&J’s recent earnings performance, and J&J’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar